The CDMO business will continue to grow: Piramal Pharma’s Nandini Piramal

Piramal Pharma, which has just completed a rights issue, has paid off Rs 958 crore of debt and now plans to focus on organic growth, cost control and operational excellence. The company is on a $1 billion growth trajectory, with revenues of Rs 1,911 crore in the second quarter. In an interview with Sohini DasChairman of Piramal Pharma Nandini Piramal outlines her plans and why she wants to focus on profitability. Edited excerpts:

What are the new global trends